A meta-analysis of the real-world effect of SGLT-2 inhibitors on CV outcomes in patients with T2DM, including fourteen trials enrolling a total of 3,157,259 patients, showed a predominant impact of SGLT2 inhibitors on CV outcomes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.